Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
BEAT Transcript
HeartBeam, Inc. (BEAT) Q1 2026 Earnings Call Transcript
Positive5-14
The earnings call summary reveals strong financial discipline, a strategic focus on high-net-worth markets, and promising product development with AI collaborations. Despite some uncertainty in patient numbers and study timelines, the Q&A indicates positive sentiment towards the subscription model and revenue potential. The recent financing strengthens the company's financial position. The overall sentiment is positive, with expectations of reaching breakeven and significant revenue scaling, suggesting a stock price increase of 2-8% over the next two weeks.
HeartBeam, Inc. (BEAT) Q4 2025 Earnings Call Transcript
Unknown3-12
The company's financial performance shows a decline in revenue, which is negative, but they have strong cash reserves. The strategic plan highlights potential growth through FDA approvals and partnerships, which is positive. The Q&A reveals some uncertainties in regulatory paths and timelines, which could cause concern. Overall, the mixed signals from financials, strategic growth plans, and uncertainties result in a neutral sentiment.
HeartBeam, Inc. (BEAT) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call reveals a mixed sentiment. While there are positive developments like productive FDA discussions and strategic partnerships, concerns arise due to limited cash reserves and lack of detailed guidance on pricing and funding. The Q&A reflects cautious optimism but lacks clarity on key issues. The strategic focus on capital efficiency and market expansion is positive, yet the absence of immediate revenue growth and the need for further funding temper expectations. Given these factors, a neutral stock price movement is anticipated over the next two weeks.
HeartBeam, Inc. (BEAT) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call presented a mixed picture: positive aspects include a decrease in operating cash use and progress towards FDA clearance, but concerns arise from the need for additional funding and lack of detailed guidance on strategic partnerships and pricing. The Q&A section did not reveal major risks but highlighted uncertainties around commercialization timelines and partnerships. The neutral sentiment stems from balancing these positive and negative elements, with no strong catalyst for significant stock movement.
BEAT Slides
BEAT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
